查看購物車
  • Simplified Chinese
  • English
  • Japanese
全球減重療法市場 - 2023-2030年
市場調查報告書
商品編碼
1290361

全球減重療法市場 - 2023-2030年

Global Weight Loss Therapeutics Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

2022年，全球減重治療市場達到27.98億美元，預計到2030年將出現有利可圖的成長，達到149.771億美元。在預測期內（2023-2030年），全球減肥治療劑市場預計將呈現24.3%的複合年成長率。

減肥療法市場範圍包括已獲批准的藥物，如Liraglutide（Saxenda）、Naltrexone-Bupropion（Contrave）、Phentermine-Topiramate（Qsymia）、Semaglutide（Wegovy）和Orlistat（Xenical，Alli）及其他，這增加了減肥療法的市場佔有率。

心血管疾病的發病率越來越高，新型藥物的研發越來越多，推動了減肥治療劑市場的需求趨勢。全球減肥治療劑市場正在擴大，因為包括治療劑的不斷進步和它們在各國即將獲得的醫療批准等因素也為減肥治療劑市場的成長創造了一個積極的前景。

市場動態

慢性疾病發病率的增加推動了減重療法市場的成長。

因為它與精神健康狀況不佳和生活品質下降有關，肥胖是一個嚴重的健康問題。此外，在美國和世界各地，它與各種類型的癌症、心臟病、糖尿病和其他主要殺手有聯繫。一個人如果超重，就更容易有高膽固醇和高血壓。這兩種疾病會增加患心臟病或中風的風險。

患心臟病或中風的可能性可以通過減少少量的體重而降低。十個患有2型糖尿病的人中有八個是肥胖或超重的。最終，高血糖促使其他健康問題，如神經損傷、視力問題、腎臟疾病、心臟病和中風。因此，越來越多的慢性疾病正在推動減肥治療劑市場的發展。

飲食習慣和生活方式的改變為製造商創造了有利可圖的機會

由於技術的進步和全球環境變化帶來的生活方式的改變，減肥療法的市場機會越來越大。推動減肥療法市場的另一個因素是成人中許多疾病的發病率不斷上升，如糖尿病和肥胖症。澳大利亞肥胖症和超重率的上升是全球趨勢的結果。

今天，高達75%的男性，超過50%的女性，以及約25%的兒童和青少年被認為是超重或肥胖的。環境和不斷變化的生活方式無疑有很大的影響，現在高能量的飯菜可以廣泛獲得，而且不再需要體育活動。因此，肥胖及其引起的健康問題在澳大利亞人中不幸變得非常頻繁。

減肥藥相關的副作用將阻礙市場的成長

為了達到最佳效果，減重藥物要與低熱量飲食和經醫生批准的運動計劃一起使用。然而，除非繼續進行飲食和運動，否則人們在停止使用減重藥物後，可能會重新獲得部分減掉的體重。

一些病人發現強化行為治療不足以幫助他們減肥。他們還糾結於與他們的體重有關的其他問題。這些可能包括荷爾蒙問題或有遺傳根源的體重問題。因此，上述這些因素限制了減肥治療劑市場的成長。

COVID-19影響分析

由於COVID-19大流行和世界上許多國家的封鎖，所有行業的公司的財務健康都受到影響。因此，在COVID-19公共衛生緊急情況期間，美國食品和藥物管理局（FDA）發布了指導方針，其中包括幫助贊助商和研究人員的一般注意事項，確保試驗參與者的安全，堅持良好的臨床實踐（GCP），並儘量減少試驗完整性的風險。

俄烏戰爭影響分析

俄羅斯-烏克蘭衝突估計對全球減重療法市場的影響不大，因為該地區的主要市場參與者數量不多。然而，在預測期內，原料進出口的影響預計對全球減重治療劑市場的成長影響不大。

目錄

第一章：方法和範圍

  • 研究方法
  • 報告的研究目標和範圍

第二章：定義和概述

第三章：執行摘要

  • 按已批准的藥物進行分析
  • 按配銷通路分類
  • 按地區分類

第四章：動態變化

  • 影響因素
    • 驅動因素
      • 主要公司的臨床試驗不斷增加
      • 慢性疾病發病率的增加
    • 限制因素
      • 減肥藥物的相關副作用
    • 機會
      • 飲食習慣和生活方式的改變
    • 影響分析

第五章：行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 監管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情況
    • COVID-19期間的情況
    • COVID-19之後的情況
  • 在COVID-19期間的定價動態
  • 需求-供應譜系
  • 大流行期間與市場有關的政府計劃
  • 製造商的戰略計劃
  • 結語

第七章：按批准藥物分類

  • 利拉魯肽(Saxenda)
  • 納曲酮-安非他酮（Contrave）
  • 芬特明-托吡酯(Qsymia)
  • 塞馬魯肽（維格威）
  • 奧利司他(Xenical, Alli)
  • Setmelanotide (Imcivree)

第8章：按配銷通路

  • 醫院藥房
  • 零售藥店
  • 網上藥店

第九章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
      • 亞太其他地區
  • 中東和非洲
    • 關鍵區域的動態

第十章：競爭格局

  • 競爭格局
  • 市場定位/佔有率分析
  • 合併和收購分析

第十一章：公司簡介

  • Novo Nordisk A/S
    • 公司概述
    • 產品組合和說明
    • 財務概況
    • 主要發展情況
  • Currax Pharmaceuticals LLC
  • Viking Therapeutics
  • Pfizer Inc.
  • Eli Lilly and Company
  • Altimmune
  • VIVUS LLC
  • Rhythm Pharmaceuticals
  • Amgen Inc.
  • Zealand Pharma A/S

第十二章：附錄

簡介目錄
Product Code: PH3616

Market Overview

The Global Weight Loss Therapeutics Market reached US$ 2,798.0 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 14,978.1 million by 2030. The global weight loss therapeutics market is expected to exhibit a CAGR of 24.3% during the forecast period (2023-2030).

The weight loss therapeutics market scope comprises approved drugs such as Liraglutide (Saxenda), Naltrexone-Bupropion (Contrave), Phentermine-Topiramate (Qsymia), Semaglutide (Wegovy) and Orlistat (Xenical, Alli) and others, which has increased the weight loss therapeutics market share.

The increasing prevalence of cardiovascular disorders and the growing research and development for novel drugs are driving up demand for weight loss therapeutics market trends. The global market for weight loss therapeutics is expanding as a result of factors including the increasing advances in therapeutics and their upcoming medical approvals across countries are also creating a positive outlook for the weight loss therapeutics market growth.

Market Dynamics

An Increase in the Incidence of Chronic Disorders Drives the Growth of the Weight Loss Therapeutics Market.

Because it is linked to poor mental wellness outcomes and a decreased quality of life, obesity is a severe health problem. Additionally, it has links to various types of cancer, heart disease, diabetes, and other major killers in the US and around the world. One is more prone to have high cholesterol and blood pressure if they are overweight. These two disorders increase the risk of developing heart disease or stroke.

The likelihood of having heart disease or a stroke can be decreased by losing a small amount of weight. Eight out of ten individuals with type 2 diabetes are obese or overweight. Eventually, high blood sugar causes other health issues such as nerve damage, vision problems, renal disease, heart disease, and stroke. Hence, the growing number of chronic disorders is driving the weight loss therapeutics market.

The Change in Food Habits and Lifestyle Creates Lucrative Opportunities for Manufacturers

Due to advancing technologies and changes in lifestyle brought on by a changing global environment, there is a growing market opportunity for weight loss therapies. Another factor driving the weight loss treatments market is the increasing prevalence of numerous illnesses among adults, such as diabetes and obesity. The rising rates of obesity and overweight in Australia are a result of a global trend.

Today, up to 75% of men, over 50% of women, and about 25% of kids and teenagers are considered overweight or obese. The environment and evolving lifestyles undoubtedly have a big impact now that high-energy meals are widely accessible and physical activity is no longer required. As an outcome, obesity and the health issues it causes have unfortunately become all too frequent in Australians.

Side Effects Associated with Weightloss Drugs Will Hamper the Growth of the Market

For optimal results, weight reduction drugs are used with a low-calorie diet and an exercise program that has been approved by a doctor. However, unless diet and exercise are continued, people may gain back part of the weight they lost after they stop using weight reduction medications.

Some patients find that intensive behavioral therapy is insufficient to help them lose weight. They also struggle with additional concerns that are related to their weight. These can include hormonal issues or weight issue that has genetic roots. Hence these above mentioned factors are limiting the weight loss therapeutics market's growth.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global weight loss therapeutics market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global weight loss therapeutics market growth over the forecast period.

Segment Analysis

The global weight loss therapeutics market is segmented based on approved drugs, distribution channel and region.

Liraglutide (Saxenda) from the Approved Drugs Segment Accounts for Approximately 32.3% of the Market Share

Liraglutide is beneficial in causing and maintaining weight loss in a population of obese people, including those with type 2 diabetes, hypertension, dyslipidemia, and obstructive sleep apnea. Liraglutide is a prescription anti-diabetic drug used for the treatment of obesity, type 2 diabetes, and persistent weight management. It is marketed under the brand name Victoza among others.

The U.S. FDA has approved an additional indication for Saxenda (liraglutide) in juvenile patients aged 12 and older who are obese, as determined by a specified body mass index (BMI), for the purpose of managing chronic weight. Saxenda is an adjuvant (extra therapy) to a low-calorie diet and increased physical exercise. Liraglutide helps patients with obesity lose weight and keep it off. Improved glycemic control is a special benefit provided by the medication.

Geographical Analysis

North America Accounted for Approximately 42.3% of the Market Share Owing to the Strong Presence of Major Players And Increasing Technological Advancements

Manufacturers have chances to expand their operations in this region because of the rising demand for weight loss therapeutics for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised the industrial production of weight loss therapeutics, which has increased the demand.

North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, industrial production has increased, fueling the demand for weight loss therapeutics.

Rising new product types or applications will drive market growth. Growth is also fueled by rising technological advancements, regulatory approvals and novel product launches. Researchers are becoming more aware of various kinds of diagnostic approaches for cancer or various other disorders, leading to the expansion of the market in this region. These factors show the dominance of North America.

Competitive Landscape

The major global players in the weight loss therapeutics market include: F Hoffmann-la Roche Ltd, Currax Pharmaceuticals LLC, Viking Therapeutics, Pfizer Inc., Eli Lilly and Company, Altimmune, VIVUS LLC, Rhythm Pharmaceuticals, Amgen Inc. and Zealand Pharma A/S among others.

Why Purchase the Report?

  • To visualize the global weight loss therapeutics market segmentation based on approved drugs, distribution channel and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of weight loss therapeutics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global weight loss therapeutics market report would provide approximately 53 tables, 54 figures and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Approved Drugs
  • 3.2. Snippet by Distribution Channel
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Rising Clinical Trials by Key Companies
      • 4.1.1.2. An Increase in the Incidence of Cronic Disorders
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effects Associated with Weighloss Drugs
    • 4.1.3. Opportunity
      • 4.1.3.1. The Change in Food Habits and Lifestyle
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Approved Drugs

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approved Drugs
    • 7.1.2. Market Attractiveness Index, By Approved Drugs
  • 7.2. Liraglutide (Saxenda) *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Naltrexone-bupropion (Contrave)
  • 7.4. Phentermine-topiramate (Qsymia)
  • 7.5. Semaglutide (Wegovy)
  • 7.6. Orlistat (Xenical, Alli)
  • 7.7. Setmelanotide (Imcivree)

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Hospital Pharmacies *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Retail Pharmacies
  • 8.4. Online Pharmacies

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approved Drugs
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. The U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approved Drugs
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. The U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approved Drugs
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approved Drugs
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan

Australia

      • 9.5.5.4. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approved Drugs
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Novo Nordisk A/S *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Currax Pharmaceuticals LLC
  • 11.3. Viking Therapeutics
  • 11.4. Pfizer Inc.
  • 11.5. Eli Lilly and Company
  • 11.6. Altimmune
  • 11.7. VIVUS LLC
  • 11.8. Rhythm Pharmaceuticals
  • 11.9. Amgen Inc.
  • 11.10. Zealand Pharma A/S

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us